Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Belgian molecular laboratory software vendor UgenTec said Thursday that it has entered into a deal with Thermo Fisher Scientific to jointly commercialize several new CE-marked respiratory assay plug-ins for its FastFinder analysis software.

On September 14, Shanghai Upper Bio-Tech Pharma Co., Ltd. was listed on the National Equities Exchange and Quotations (NEEQ) in China market. The transaction method is call auction, and the level to which it belongs is the basic layer.

DiaSorin said Wednesday it had gained US Food and Drug Administration 510(k) clearance for a swab-based COVID-19 PCR assay that delivers results in about one hour.

Illumina said on Wednesday that its Illumina Accelerator program has invested in six new startups from around the world.

Recently, the AutraMic mini4800 Plus developed by Shanghai ZJ Bio-Tech Co.,Ltd. was approved by National Medical Products Administration. It was the smallest and more automated integrated magnetic bead method + fluorescent PCR nucleic acid detection system.

NanoSpot.ai and Athroa subsidiary Opto announced Tuesday a commercial and distribution partnership for European sales of NanoSpot.ai's point-of-care SARS-CoV-2 Total Antibody Test.

Oxford Nanopore Technologies reported on Tuesday morning that its revenues in the first half of 2022 more than doubled year over year, driven by COVID-19 testing.

It was reported on September 9 that Lanyu Bio, a domestic high-tech enterprise for in vitro diagnostics, announced the completion of the D2 round of financing of nearly CNY 100 million.

MagBio Genomics said on Monday that it has received US Food and Drug Administration 510(k) clearance, as well as CE marking, for its MagXtract Collection Tube for viral sample collection.

Adaptive Biotechnologies on Monday said that it has signed a nondilutive financing agreement with investment firm OrbiMed that will give it access to as much as $250 million in exchange for a portion of its revenues.